Navigation Links
Aggressive Cholesterol, Blood Pressure Treatment Shows Some Benefit
Date:4/8/2008

But jury still out on whether it makes difference in high-risk groups, study finds

TUESDAY, April 8 (HealthDay News) -- A new study that weighed whether aggressively lowering cholesterol levels and blood pressure in people at high risk of heart disease is worth the effort did not produce a definitive answer to the question.

The research, which involved 499 American Indians with diabetes, found the strategy led to some improvements without producing dangerous side effects, said Barbara V. Howard, lead author of the report in the April 9 issue of the Journal of the American Medical Association.

"This is the first trial that really tested targeting," said Howard, a senior scientist with the Medstar Research Institute in Maryland. "Until now, clinical trials have meant taking a drug and escalating the dose and comparing the reduction in heart disease. Our goal was to target people at high risk and test lower targets for both risk factors hypertension and LDL cholesterol. What we showed is that you can reach those lower targets safely."

The improvement seen was a reduction in the thickening of the walls of the carotid artery, the main artery to the brain. However, no difference in the rate of adverse events was seen between those who had the most aggressive treatment and those who had standard treatment. "But there have been no trials where the carotid measurements did not correlate eventually with what happened in the endpoints," Howard noted.

The main conclusion of the trial is that "we see improvement with lower targets, but we need longer studies," Howard noted.

So, what should be done with the millions of Americans at increased coronary risk because, like the people in the trial, they have diabetes?

"What it says is that more aggressive targets than have been traditionally recommended can be achieved, can be achieved safely, and are associated with regression of plaque build-up in the carotid artery," said study leader Dr. Mary J. Roman, a professor of medicine at Weill Cornell Medical College.

To achieve the LDL cholesterol target, a blood level of 70, "I would still consider using ezetimibe [a second-line, cholesterol-lowering drug] in people who cannot tolerate statins and people who cannot achieve the target with maximum doses of statins or other medication," Roman said.

And while the incidence of side effects was higher in those treated aggressively for high blood pressure, Roman said, "aiming for that target has a beneficial effect. It is always easy to back off and not be as aggressive."

There was some disagreement on aggressive treatment of high blood pressure from Dr. Eric D. Peterson, a professor of medicine at Duke University, and author of an accompanying editorial.

"It would seem, based on what we have here, hard to justify ultraintensive hypertension reduction when we haven't shown benefit from a clinical viewpoint," Peterson said.

But with LDL cholesterol, "many arguments can be made for aggressive treatment in diabetic populations," he said.

The side effects of aggressive LDL cholesterol-lowering treatment are "minimal," Peterson said, and the addition of ezetimibe (Zetia) to statin treatment in some cases "seems to be reasonable."

"But ezetimibe has been a second-line agent," he said. "I would never use it as a first-line agent."

Ezetimibe has also been the subject of controversy in recent months as trials have started to show that adding the drug to statin treatment produces no benefit in reducing plaque build-up in blood vessels.

More information

The links between diabetes and heart disease are outlined by the American Diabetes Association.



SOURCES: Barbara V. Howard, Ph.D., senior scientist, MedStar Research Institute, Hyattsville, Md.; Mary J. Roman, M.D., professor, medicine, Weill Cornell Medical College, New York City; Eric D. Peterson, M.D., professor, medicine, Duke University, Durham, N.C.; April 9, 2008, Journal of the American Medical Association


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
2. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
3. AWT Management Announce Aggressive Growth and Acquisition Strategy
4. Novel strategy under study for aggressive leukemia
5. Prostate cancer more likely to return in blacks than whites, but the disease is not more aggressive
6. Mayo Clinic tests novel vaccine for aggressive brain tumors
7. Aggressively Treating Cardiac Risk Factors May Reverse Ischemia
8. Breast cancer is more aggressive in African-American women
9. Gene Variant Tied to More Aggressive Prostate Cancer
10. Study finds gene linked to aggressive prostate cancer
11. Even tiny breast tumors can be aggressive and may require maximum therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Aggressive Cholesterol, Blood Pressure Treatment Shows Some Benefit
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: